Cellenkos, Inc. Appoints Elizabeth Read as Chief Technology Officer, Adding Technology and Regulatory Affairs Expertise to its Executive Team

HOUSTON, Jan. 8, 2019 -- (Healthcare Sales & Marketing Network) -- Cellenkos® (Cellenkos), an early stage clinical biotechnology company developing umbilical cord blood-derived T-regulatory (Treg) cellular therapies for the treatment of autoimmune dis... Biopharmaceuticals, Personnel Cellenkos, cord blood, regulatory T cells, cellular therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news